New combo therapy aims to tame Graft-Versus-Host disease after stem cell transplant
NCT ID NCT07576010
First seen May 09, 2026 · Last updated May 09, 2026
Summary
This early-phase study tests whether combining low-dose steroids with the drug ruxolitinib can better control grade II acute graft-versus-host disease (aGVHD) after a stem cell transplant. About 30 participants with certain blood cancers will receive this combination as their first treatment. The goal is to improve survival without severe GVHD or relapse, while monitoring safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE GRAFT-VERSUS-HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
Conditions
Explore the condition pages connected to this study.